Skip to main content
. 2018 May 8;2:13. doi: 10.1038/s41698-018-0056-z

Fig. 1.

Fig. 1

Hypertension and heart failure with sunitinib. Percentage of renal cell cancer patients free of hypertension and with various grades of hypertension (a) or heart failure (b) after initiation of sunitinib therapy. Modified from ref. 7